HeXun Biosciences Co., Ltd. (TPEX:6986)

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	304.45	286.42	130.57	49.47	-
Revenue Growth (YoY)	28.78%	119.36%	163.94%	-	-
Cost of Revenue	26.85	25.75	16.84	4.86	-
Gross Profit	277.6	260.67	113.73	44.61	-
Selling, General & Admin	48.55	39.57	33.14	14.23	5.95
Research & Development	76.26	65.37	53.22	39.36	44.71
Operating Expenses	124.81	104.94	86.36	53.59	50.66
Operating Income	152.79	155.73	27.37	-8.98	-50.66
Interest Expense	-1.08	-1.18	-1.85	-1.64	-1.57
Interest & Investment Income	5.39	4.41	2.79	0.46	0.03
Currency Exchange Gain (Loss)	-0.79	-0.79	0.53	0.02	-
Other Non Operating Income (Expenses)	-1.22	3.3	4.7	4.93	9.01
EBT Excluding Unusual Items	155.08	161.48	33.54	-5.21	-43.19
Gain (Loss) on Sale of Assets	-0.01	-0.01	-0.05	0.02	0.2
Pretax Income	155.08	161.47	33.49	-5.19	-42.99
Income Tax Expense	23.76	14.25	-	-	-
Net Income	131.32	147.22	33.49	-5.19	-42.99
Net Income to Common	131.32	147.22	33.49	-5.19	-42.99
Net Income Growth	5.72%	339.62%	-	-	-
Shares Outstanding (Basic)	46	46	45	38	31
Shares Outstanding (Diluted)	46	46	45	38	31
Shares Change (YoY)	0.16%	1.61%	20.81%	22.92%	-
EPS (Basic)	2.85	3.20	0.74	-0.14	-1.41
EPS (Diluted)	2.85	3.20	0.74	-0.14	-1.41
EPS Growth	5.67%	332.90%	-	-	-
Free Cash Flow	152.42	83.63	22.42	10	-35.5
Free Cash Flow Per Share	3.31	1.82	0.49	0.27	-1.16
Gross Margin	91.18%	91.01%	87.10%	90.18%	-
Operating Margin	50.18%	54.37%	20.96%	-18.15%	-
Profit Margin	43.13%	51.40%	25.65%	-10.49%	-
Free Cash Flow Margin	50.07%	29.20%	17.17%	20.22%	-
EBITDA	175.26	175.88	43.12	2.58	-41.87
EBITDA Margin	57.56%	61.41%	33.03%	5.21%	-
D&A For EBITDA	22.47	20.15	15.75	11.56	8.8
EBIT	152.79	155.73	27.37	-8.98	-50.66
EBIT Margin	50.18%	54.37%	20.96%	-18.15%	-
Effective Tax Rate	15.32%	8.82%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.